AzTrials
AzTrials

Stroke SequelaeCESTONCT07635069

Cognitive Effectiveness of Somatotherapy and Occupational Therapy in Post-Stroke Patients.

An observational study of Stroke Sequelae and Cognitive Impairment, run by Iqra National University at 1 site in Pakistan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The objective of this study was to evaluate the cognitive effectiveness of somatotherapy and occupational therapy in post-stroke patients by measuring their cognitive potential outcomes using the Montreal Cognitive Assessment (MoCA) test. Read more about this study

Who is it for?
Ages 30 years and older
Conditions the study is for
Stroke Sequelae, Cognitive Impairment
What is being tested?
Somatotherapy and Occupational Therapy
How many people
50 participants
Where
1 sitePakistan
Study dates
3 Jan 2023to 25 Dec 2025
How long will I take part?
50 Months
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: 50 post-stroke patients (30 males and 20 females) who were referred to the Department of Physical Therapy at King Hospital, Swat, Pakistan between 2018 and 2019 for cognitive rehabilitation. Participants were adult stroke patients (approximate mean age around 60 years) with either ischemic or hemorrhagic stroke who received 4 weeks of inpatient combined somatotherapy and occupational therapy.

Who may be able to join

  • Adults aged 30 years and above
  • Diagnosed with ischemic or hemorrhagic stroke (first-ever or recurrent)
  • Referred to physical therapy department for cognitive rehabilitation
  • Received somatotherapy and occupational therapy during hospitalization
  • Able to undergo MoCA (Montreal Cognitive Assessment) testing

Who cannot join

  • Severe speech impairment (aphasia) that prevents reliable cognitive testing
  • Significant visual impairment that interferes with MoCA testing
  • Significant hearing impairment that interferes with MoCA testing
  • Inability to participate in therapy sessions.

Trial locations and contacts

1 site in 1 country.

Pakistan1 site
  • Swat Medical Complex

    Swat, Khyber Pakhtunkhwa, 26000

Other trials in Pakistan

About this study

Official title: The Cognitive Effectiveness of Somatotherapy & Occupational Therapy in Post-Stroke Patients

The objective of this study was to evaluate the cognitive effectiveness of somatotherapy and occupational therapy in post-stroke patients by measuring their cognitive potential outcomes using the Montreal Cognitive Assessment (MoCA) test.

Read the detailed description

Stroke is a leading cause of death and long-term disability worldwide. Cognitive impairment is a common and disabling consequence of stroke that significantly affects patients' functional independence and quality of life.

Somatotherapy (targeted physical and sensorimotor therapy) and occupational therapy (focused on activities of daily living) are frequently used rehabilitation approaches, but their combined effect on cognitive recovery in post-stroke patients requires further evaluation.

This was a single-center, retrospective observational study conducted at the department of physical therapy, King Hospital, Swat, Pakistan. Medical records of 50 post-stroke patients (30 males, 20 females; age range 30-60 years) who received inpatient rehabilitation between 2018 and 2019 were analyzed.

Participants

Being tested
Somatotherapy and Occupational Therapy
Keywords
stroke, stroke sequelae, Cognitive Impairement
Medical subject headings
Cognitive Dysfunction, Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Somatotherapy and Occupational TherapyOther

    Combined somatotherapy and occupational therapy delivered during inpatient hospitalization.

    Somatotherapy consisted of structured sensorimotor and physical therapy targeting body awareness, movement, balance, and coordination. Occupational therapy focused on patient-specific, task-oriented training in activities of daily living (ADLs) such as self-care, functional mobility, and cognitive integration during daily tasks.

    Patients received 35-minute sessions, 5 days per week for 4 consecutive weeks. Therapy was customized according to individual patient needs and used equipment including adjustable tables, chairs, wheelchairs, and assistive aids (splints, glasses, etc.).

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Montreal Cognitive Assessment

    To detect mild cognitive impairment and assess for early stages of dementia. This scale utilizes a minimum value of 0 and a maximum value of 30, where higher scores mean a better outcome (a score of 26 or above is considered normal, while a score of 22 suggests mild cognitive impairment.

    Measured: 4 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Jun 2026
  2. Study start3 Jan 2023
  3. Primary completion25 Dec 2025
  4. Study completion25 Dec 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Other
Enrolment
50 participants (actual)
Target duration
50 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT07635069
Sponsor's protocol ID
IQRA-00023
Other IDs
Iqra-023
Acronym
CESTO
Status last verified
Jun 2026
First submitted
8 May 2026
Last updated
9 Jun 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: ndividual participant data will not be shared publicly. The study is a small retrospective analysis based on hospital medical records. Sharing IPD is not planned due to: Ethical and privacy concerns (patient confidentiality and data protection regulations). The retrospective nature of the study with no prior consent obtained from participants for data sharing. Local institutional policies at King Hospital regarding data sharing.

Questions about this trial

What is this clinical trial studying?

An observational study of Stroke Sequelae and Cognitive Impairment, run by Iqra National University at 1 site in Pakistan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Montreal Cognitive Assessment (time frame: 4 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jun 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in